MI-ONESTREAM-SOFTWARE
29.3.2021 12:02:05 CEST | Business Wire | Press release
OneStream Software , a leading provider of modern corporate performance management (CPM) solutions for mid-sized to large enterprises, has been recognized as a market leader in the Business Application Research Center’s (BARC) global report on financial performance management software solutions. The BARC Score Financial Performance Management Global 2021 report places OneStream as a market leader with among the highest Portfolio Capabilities scores across vendors.
After hiring more than 270 employees throughout 2020, the company exceeded its 2020 projections and achieved 85 percent growth in Annual Recurring Revenue (ARR), accumulating more than 650 customers and achieving triple digit ARR CAGR in the EMEA region from 2017-2020. OneStream closed the year with 690 employees across 15 countries and more than 200 partners worldwide including PWC, Accenture and other general advisory firms. OneStream will continue to expand its workforce and partner ecosystem in 2021, including its opening of an Asia-Pacific (APAC) headquarters in Sydney, Australia.
“For OneStream to be recognized as a market leader in only the second year of coverage in the BARC Score report for Financial Performance Management solutions for global vendors reflects the broad capabilities of the platform and strong market adoption for global organizations worldwide. OneStream’s growth trajectory and commitment to 100% customer success positions the company to continue to challenge more established vendors as a leader in this market,” said Dr. Christian Fuchs, Senior Vice-President and Head of Data & Analytics Research at BARC.
The BARC Score report noted OneStream’s unified CPM platform for financial consolidation, close reporting and planning with built-in financial analytic engine and financial data quality capabilities as a strength, along with integrated analysis and reporting functionality. BARC also identified the OneStream MarketPlace, which hosts more than 50 downloadable business and productivity solutions optimized for the platform, as another strength. Overall, the report cited OneStream as having “excellent customer feedback for many important KPIs in BARC’s Planning Survey.”
“We are proud to be recognized in the BARC Score Financial Performance Management Global report as a market leader,” said Ricardo Rasche, Senior Vice President of International Sales for OneStream Software. “The BARC Score validates our underlying commitment to delivering 100% customer success for global organizations based in Germany, Austria, Switzerland and across the world. We are honored by this distinction as a market leader among much more established legacy vendors in EMEA.”
Last year in BARC’s The Planning Survey 20 , OneStream earned 38 top ranks and a 97% customer recommendation score. The BARC Score Financial Performance Management Global report examines global vendors, evaluating different criteria on two axes, “Portfolio Capabilities” and “Market Execution.” Vendors evaluated generated more than 20 million EUR in license revenue per year with its product set across EMEA, North America, Latin America and/or Asia-Pacific.
OneStream is helping a growing list of companies worldwide digitally transform finance and support strategic business decisions across the enterprise. OneStream customers are able to replace multiple legacy applications with OneStream’s unified Intelligent Finance platform and streamline key finance processes. Valued at more than $1B in 2019 and backed by global investment firm KKR, OneStream recently announced 2020 results and is well poised for a strong 2021.
To download the full report, click here .
About OneStream Software
OneStream Software provides a market-leading intelligent finance platform that reduces the complexity of financial operations. OneStream unleashes the power of finance by unifying corporate performance management (CPM) processes such as planning, financial close & consolidation, reporting and analytics through a single, extensible solution. We empower the enterprise with financial and operational insights to support faster and more informed decision-making. All in a cloud platform designed to continually evolve and scale with your organization.
OneStream is an independent software company backed by private equity investor KKR. With over 600 customers, 200 partners and over 700 employees our primary mission is to deliver 100% customer success. To learn more visit www.onestreamsoftware.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005071/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom